Comparison
17 20 Lyase Deficiency Isolated Included CN372394 vs 13q12 3 Microdeletion Syndrome C4750951
Clinical comparison between 17 20 Lyase Deficiency Isolated Included CN372394 and 13q12 3 Microdeletion Syndrome for differential diagnosis and treatment planning.
6 comparison axes
Onset
17 20 Lyase Deficiency Isolated Included CN372394
0-16
13q12 3 Microdeletion Syndrome C4750951
0-null
Onset patterns differ
Severity
17 20 Lyase Deficiency Isolated Included CN372394
severe
13q12 3 Microdeletion Syndrome C4750951
moderate
Different severity levels
Chronic
17 20 Lyase Deficiency Isolated Included CN372394
Chronic
13q12 3 Microdeletion Syndrome C4750951
Chronic
Differing course
Communicable
17 20 Lyase Deficiency Isolated Included CN372394
No
13q12 3 Microdeletion Syndrome C4750951
No
Different transmission
Body System
17 20 Lyase Deficiency Isolated Included CN372394
endocrine
13q12 3 Microdeletion Syndrome C4750951
congenital
Same/different system
Category
17 20 Lyase Deficiency Isolated Included CN372394
endocrine
13q12 3 Microdeletion Syndrome C4750951
genetic
Different category
Bottom line
17-20-lyase-deficiency-isolated-included-CN372394 and 13q12-3-microdeletion-syndrome-C4750951 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 20 Lyase Deficiency Isolated Included CN372394 | 13q12 3 Microdeletion Syndrome C4750951 | Discriminating power |
|---|---|---|---|
| Sex-steroid development | May involve undervirilization or delayed puberty from impaired sex-steroid production; exact features vary. | No established primary sex-steroid defect; developmental concerns may occur for other reasons. | Moderate |
| Developmental pattern | Primarily an endocrine presentation rather than a defined multisystem developmental syndrome. | May include developmental and medical concerns related to missing chromosome 13 material. | Moderate |
| Onset context | Reported onset range is childhood through adolescence, but timing is not uniform. | Congenital chromosomal change is present from birth; clinical recognition timing is not established. | Low |
When to favor each condition
Choose 17 20 Lyase Deficiency Isolated Included CN372394 when
Disordered puberty or sex development suggests a steroid pathway problem
Isolated 17,20-lyase deficiency is categorized as endocrine and may impair sex-steroid synthesis.
Moderate
Cortisol deficiency is not the leading concern
The isolated form is distinguished conceptually from broader adrenal enzyme defects, but confirmation requires specialist testing.
Low
No chromosomal deletion has been identified
A negative relevant genetic study would make the microdeletion less likely, without proving the enzyme disorder.
Moderate
Choose 13q12 3 Microdeletion Syndrome C4750951 when
A chromosomal microarray finds a 13q12.3 deletion
The syndrome is defined by missing chromosomal material, not by an endocrine enzyme result.
High
Multiple congenital or developmental concerns need syndrome evaluation
The supplied description supports varied developmental and medical concerns with supportive care.
Moderate
Steroid testing does not explain the overall phenotype
A broader congenital genetic condition may fit better than an isolated endocrine disorder.
Low
How key tests differ
| Test | 17 20 Lyase Deficiency Isolated Included CN372394 | 13q12 3 Microdeletion Syndrome C4750951 | Interpretation |
|---|---|---|---|
| Steroid profile | May suggest impaired sex-steroid synthesis; no cutoff is supplied here. | No characteristic steroid abnormality is established. | An abnormal profile is not itself a diagnosis and needs endocrine interpretation. |
| Chromosomal microarray | Not expected to define this enzyme disorder. | May identify a small deletion at 13q12.3. | A detected deletion supports the syndrome; absence does not exclude all genetic disease. |
| Gene or enzyme evaluation | Specialist testing may assess the relevant steroidogenic pathway. | Evaluation centers on the chromosomal deletion rather than an enzyme assay. | Test selection should follow clinical genetics or endocrinology review. |
Prognosis comparison
17 20 Lyase Deficiency Isolated Included CN372394
- Outcome
- Long-term outcome is not established; endocrine effects may be significant.
- Factors
- Pubertal status, confirmed biochemistry or genetics, and specialist follow-up.
13q12 3 Microdeletion Syndrome C4750951
- Outcome
- Often described as moderate, but individual prognosis is not established.
- Factors
- Deletion findings, developmental needs, and associated medical issues.
Time frame: Lifelong, with needs potentially changing from childhood onward.
Precise diagnosis, associated anomalies, access to coordinated care, and individual development.
Complications comparison
| Complication | Presentation |
|---|---|
| Pubertal or reproductive effects | Sex-steroid deficiency may affect puberty or fertility, but outcomes are not uniform. Reproductive effects are not established from the supplied description. Avoid assuming infertility or a specific treatment need. |
| Developmental complications | Not described as a primary developmental syndrome. Developmental concerns may occur and require individualized support. Severity and specific deficits are not established here. |
| Associated medical needs | Endocrine monitoring may be needed; doses and protocols are not specified. Care is supportive and tailored; complication rates are not supplied. Neither condition is communicable. |
Patient education highlights
- HighDifferent causes
One is an endocrine steroid-pathway disorder; the other is a rare chromosomal microdeletion.
- HighTesting limits
An abnormal laboratory result or genetic finding needs clinician interpretation and does not alone determine care.
- MediumIndividual course
Both are chronic, but severity, symptoms, and support needs can differ between people.